Clinical trials: Patients With Metabolic Syndrome
Respiratory Failure, Neuromuscular Disease
Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Acute Exacerbation of Respiratory Failure
The aim of the study is to compare the efficacy and tolerance of autotitrating non-invasive ventilation (NIV) versus standard NIV in patients admitted to hospital with acute exacerbation of chronic respiratory failure.
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01174316
- Testing
- AutoVPAP™, VPAPIIIST-A™
- Where
- United Kingdom
- Sponsor
- ResMed
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Hypertension, Metabolic Disorder
A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
To determine if a one year treatment Losartan with or without HCTZ at different dosages have an effect on metabolic parameters in patients with hypertension and the metabolic syndrome.
- Trial name
- NCT00546052
- Testing
- losartan potassium (+) hydrochlorothiazide
- Volunteers
- 1,738 people
- Sponsor
- Organon and Co
Metabolic Syndrome
Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome
The primary objective of the study is to assess the efficacy of STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome during 12 weeks of consumption.
- Trial name
- OBEMINALE2 (NCT03692806)
- Testing
- Stablor
- Where
- 6 sites in France, Ireland
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- LNC THERAPEUTICS
Short Bowel Syndrome (SBS)
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
The purpose of this study is to understand the safety and efficacy of twice weekly glepaglutide 10 mg in adult patients with short bowel syndrome (SBS), who were previously enrolled in the EASE SBS 2 or EASE SBS 3 trials.
- Trial name
- EASE SBS 6 (NCT07228403)
- Testing
- Glepaglutide 10 mg
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 28 people
- Sponsor
- Zealand Pharma
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Chronic Respiratory Failure With Hypercapnia, Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Telemonitoring and Experimentation in Telemedicine for the Improvement of Healthcare Pathways (ETAPES Program) Compared to Standard of Care in Patients With Chronic Respiratory Failure Receiving Non-invasive Home Ventilation
The ETAPES Program, a French national Experimentation in Telemedicine for the Improvement of Healthcare Pathways, was launched in 2018 for 4 years.
- Conditions
- Chronic Respiratory Failure With Hypercapnia, Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS)
- Trial name
- e-VENT (NCT04615078)
- Testing
- ETAPES Program
- Where
- 11 sites in France
- Volunteers
- 56 people
- Sponsor
- Air Liquide Santé International
Metabolic Syndrome
Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)
The purpose of this study was to assess the incidence rate of the major adverse cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin therapy in patients who have history of acute myocardial…
- Trial name
- NCT02069717
- Testing
- Not applicable-observational study
- Where
- South Korea
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Metabolic Syndrome
The BANGALORE Study; Combination of Berberine, Lipoic Acid, and Picrorhiza
Though medical treatment has been effective in the treatment of cardiometabolic diseases (including coronary atherosclerosis and diabetes mellitus), the incidence of these disorders continues to be high.
- Trial name
- CAR-191 (NCT01696448)
- Testing
- CAR-191
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Carmel Biosciences
Diabetes Mellitus
Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin
The purpose of this study is to measure microcirculation in type 2 diabetes patients with peripheral edema who are taking pioglitazone, once daily (QD).
- Trial name
- NCT00676260
- Testing
- Pioglitazone
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- Takeda
Bile Acid Synthesis Disorders
The REPLACE Registry for Cholbam® (Cholic Acid)
This is a prospective, observational, non-interventional patient registry study designed to document product safety and effectiveness outcomes for 10 years in patients treated with Cholbam, including those who have been using…
- Trial name
- NCT03115086
- Testing
- Cholbam
- Where
- 24 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Myelodysplastic Syndrome, Thalassemia
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
This study will evaluate the efficacy and safety of deferasirox in patients with MDS, thalassemia and rare anemia patients with transfusion iron overload.
- Trial name
- NCT01250951
- Testing
- Deferasirox
- Where
- 2 sites in Russia
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Diseases, Chronic Renal Insufficiency
Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
Approximately 207 patients with chronic kidney disease (CKD) on hemodialysis will be entered into this study at approximately 26 centers in the United States.
- Conditions
- Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
- Trial name
- NCT00268957
- Testing
- Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
- Where
- 29 sites in United States
- Volunteers
- 217 people
- Sponsor
- Genzyme, a Sanofi Company
Mucopolysaccharidosis II
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)
The purpose of this study is to determine whether the administration of iduronate-2-sulfatase enzyme in a weekly or every other week therapy frequency is safe and efficacious in patients with MPS II.
- Trial name
- NCT00069641
- Testing
- Iduronate-2-sulfatase enzyme replacement therapy
- Where
- 9 sites in United States, Brazil and 2 more
- Volunteers
- 96 people
- Sponsor
- Shire
Mucopolysaccharidosis IVA, Morquio A Syndrome
BMN 110 US Expanded Access Program
The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available 2.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01858103
- Testing
- BMN 110
- Where
- 25 sites in United States, Puerto Rico
- Sponsor
- BioMarin Pharmaceutical
NAFLD, Obesity
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2…
- Conditions
- NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias
- Trial name
- NCT05872269
- Testing
- Saroglitazar
- Where
- 19 sites in India
- Volunteers
- 1,500 people
- Sponsor
- Zydus Lifesciences Limited
Myelodysplastic Syndromes, Beta-Thalassemia
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload
- Trial name
- NCT00564941
- Testing
- deferasirox
- Where
- 4 sites in Hungary
- Volunteers
- 309 people
- Sponsor
- Novartis Pharmaceuticals
Metabolic Syndrome, Hypertension
Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome
The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00110422
- Testing
- Irbesartan, Hydrochlorothiazide
- Where
- 25 sites in France, Germany and 4 more
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission.
- Trial name
- ACS (NCT07102628)
- Testing
- Inclisiran
- Where
- 69 sites in Argentina, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Celiac Disease
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
To assess the efficacy and safety of larazotide acetate versus placebo for the relief of persistent symptoms in adult celiac disease patients.
- Trial name
- NCT03569007
- Testing
- Larazotide
- Where
- 160 sites in United States
- Volunteers
- 307 people
- Sponsor
- 9 Meters Biopharma, Inc.